Navigation Links
Transplanted cells may hold the key to curing hemophilia A, Einstein scientists report

Scientists at the Albert Einstein College of Medicine of Yeshiva University have shown for the first time that transplanted cells can cure hemophilia A (the most common form of the disease) in an animal model. Their study appears online February 14 in the Journal of Clinical Investigation.

Hemophilia A affects one in 10,000 males and is characterized by recurrent, spontaneous bleeding that can cause disability or death. It has, most famously, affected British and Russian nobility, along with countless others. The Einstein team, led by Dr. Sanjeev Gupta, cured hemophilia A by transplanting healthy liver endothelial cells from donor mice into a mouse model of the disease. In curing these mice, the Einstein researchers also overturned conventional wisdom regarding which cells produce factor VIII, the crucial clotting protein that is lacking in people with type A hemophilia.

Weve known for three decades that factor VIII is produced in the liver, but precisely where has been controversial, says Dr. Gupta, a professor in the departments of medicine and pathology at Einstein. It was assumed that factor VIII was made by the hepatocytescells that perform many of the livers functions and comprise most of its bulk. But our research had suggested that the primary sources were special endothelial cells that line the sinusoids, the livers blood-filled spaces. We did this study to confirm the role of liver endothelial cells in producing factor VIII and to see if transplanting them from a healthy donor liver could correct hemophilia A in an animal model.

The donor mice used by Dr. Guptas team had been genetically engineered so that their endothelial cells expressed the gene for green fluorescent protein. This allowed the researchers to see whether the liver endothelial cellsisolated from donor livers and then injected into a vein leading into the liver of recipient hemophilia A micecould successfully engraft within the recipients livers. Before transplantation, to make room for the donated cells to engraft and proliferate, the researchers gave recipient mice a dose of the toxic chemical monocrotaline to deplete their native liver endothelial cells.

Three months after transplantation, when we examined the livers of recipient mice, we found that the transplanted cells had engrafted and increased in number, says Dr. Antonia Follenzi, an instructor in pathology at Einstein and the lead author of the study. Even more important, those mice with the most transplanted cells in their livers produced factor VIII in sufficient amounts to completely correct their hemophilia A.

Efforts up until now to cure hemophiliaranging from faith healing by the Russian monk Rasputin early in the 20th century to clinical trials in the U.S. using gene therapyhave had limited or no success. While the Einstein study marks a significant advance against hemophilia A, Dr. Gupta cautions that more work is necessary before liver-cell transplants can be attempted on people. An important need, he says, is for safer alternatives to monocrotaline, the chemical we gave to recipient mice to create space for healthy donor liver cells. Fortunately, several drugs already in clinical use hold promise in that regard.

The principle established by this studyselectively injuring native endothelial cells and replacing them with healthy donor endothelial cellsmight also help in treating hemophilia B (the less common form of the disorder) and, more broadly, aid in tissue engineering in the many other areas of the body where endothelial cells are found, says Dr. Gupta. For example, he notes that endothelial cells isolated from blood vessels and transplanted into the heart could help in treating cardiovascular disease. In addition, he says that it may be possible to deliver therapeutic substances into the liver and other organs by combining gene therapy with the cell-transplantation approach used in this study.


Contact: Karen Gardner
Albert Einstein College of Medicine

Related biology technology :

1. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
2. CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board
3. Historic Breakthrough in Fighting Childrens Batten Disease as China Stem Cells Give New Lease on Life to 6 Year Old California Boy
4. Stemagen First to Create Cloned Human Embryos From Adult Cells
5. Researchers use magnetism to target cells to animal arteries
6. Solar cells of the future
7. New use for stem cells found in war on terrorism
8. UW-Madison scientists guide human skin cells to embryonic state
9. Shinya Yamanaka reprograms human adult cells
10. Discovery Institute Bioethicist Lauds Breakthrough in Stem Cells Research that Eliminates Need for Human Cloning
11. STEM CELLS Journal Names Co-Editors
Post Your Comments:
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... InSphero AG, ... 3D cell culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... Aregger served on the management team and was promoted to Head of ...
(Date:11/24/2015)... ANGELES , Nov. 24, 2015 ... biotechnology company focused on the discovery, development and commercialization ... , Ph.D., Chief Executive Officer, is scheduled to present ... 1, 2015 at 10:50 a.m. EST, at The Lotte ... City . . ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
Breaking Biology News(10 mins):